Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
5500 Wayzata Blvd Ste 1600
Golden Valley, Minnesota 55416-1237
Phone: 17639575037
www.inspiremedicalsystems.com
Inspire Medical Systems Inc (INSP) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Positive Financial Outlook
Q2 2024 Inspire Medical Systems Inc Earnings Call Transcript
No summary available.
Inspire Medical Systems (NYSE: INSP ) just reported results for the second quarter of 2024. Inspire Medical Systems reported earnings per share of 32 cents. This was above the analyst estimate for EPS of -15 cents. The company reported revenue of $195.89 million. This was 5.21% better than the analyst estimate for revenue of $186.19 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post INSP Stock Earnings: Inspire Medical Systems Beats EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .
Inspire Medical Systems press release (INSP): Q2 GAAP EPS of $0.32 beats by $0.46. Revenue of $195.9M (+29.6% Y/Y) in-line. As of June 30, 2024, cash, cash equivalents, and investments
Inspire Medical Systems (INSP) stock rose 3% after the FDA approved its Inspire V therapy system for obstructive sleep apnea. Read more here.
Inspire Medical Systems, Inc. The post Inspire Medical Receives FDA Approval For Next Generation Inspire Neurostimulation System appeared first on ForexTV .
MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the FDA approval of the Inspire V therapy system which includes the next generation neurostimulator and the associated Bluetooth® patient remote and physician programmer.
Inspire Medical''s FDA-approved Inspire V therapy system offers new hope for obstructive sleep apnea patients. Discover how this innovative neurostimulator is set to transform OSA treatment, launching late 2024.
